Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

ClinicalTrials.gov ID: NCT02659397

Public ClinicalTrials.gov record NCT02659397. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Adding ETC-1002 180 mg to Atorvastatin 80 mg Background Therapy in Statin-Treated Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this research study is to measure the amount of atorvastatin and ETC-1002 in the blood, to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine, and to see how ETC-1002 is tolerated in the body compared to placebo when added to stable atorvastatin 80 mg background therapy in statin-treated patients.

Study identification

NCT ID
NCT02659397
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Enrollment
68 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2015 (Type not available)
Primary completion
Jul 2016 (Actual)
Completion
Jul 2016 (Actual)
Last update posted
Mar 29, 2019

2015 – 2016

United States locations

U.S. sites
19
U.S. states
11
U.S. cities
19
Facility City State ZIP Site status
Not listed Anaheim California 92801 —
Not listed Los Angeles California 90057 —
Not listed Northridge California 91324 —
Not listed Clearwater Florida 33765 —
Not listed Jacksonville Florida 32216 —
Not listed Miami Florida 33126 —
Not listed Port Orange Florida 32127 —
Not listed Boise Idaho 83642 —
Not listed Chicago Illinois 60607 —
Not listed Springfield Illinois 62711 —
Not listed Louisville Kentucky 40213 —
Not listed Berlin New Jersey 08009 —
Not listed Rapid City South Dakota 57701 —
Not listed Carrollton Texas 75006 —
Not listed West Jordan Utah 84088 —
Not listed Arlington Virginia 22203 —
Not listed Lynchburg Virginia 24501 —
Not listed Richmond Virginia 23294 —
Not listed Renton Washington 98057 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02659397, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2019 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02659397 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →